誉衡药业公告，2025年上半年，公司实现营业收入11亿元，同比下降9.97%；归属于上市公司股东的净 利润1.34亿元，同比增长7.56%；基本每股收益0.0613元/股，同比增长10.25%。 ...

哈尔滨誉衡药业股份有限公司 2025 年半年度报告 2025 年 8 月 第 1页 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或者重大遗漏，并承担个别和连带的法律责任。 证券代码：002437 证券简称：誉衡药业 公告编号：2025-062 公司负责人国磊峰、主管会计工作负责人国磊峰及会计机构负责人(会计主管人员)周小婧声明：保证本半年度报告 中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本公司风险因素详见"第三节 管理层讨论与分析-十、公司面临的风险和应对措施" 公司计划不派发现金红利，不送红股，不以公积金转增股本。 第 2页 | 第一节 | 重要提示、目录和释义 | | 2 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | | 6 | | 第三节 | 管理层讨论与分析 | | 9 | | 第四节 | 公司治理、环境和社会 | | 20 | | 第五节 | 重要事项 | | 23 | | 第六节 | 股份变动及股东情况 | | ...

Group 1 - The core point of the article is that Yuheng Pharmaceutical has seen a decrease in the number of shareholders and fluctuations in its stock price, alongside mixed financial performance in the first quarter [2] Group 2 - As of August 10, the number of shareholders for Yuheng Pharmaceutical was 121,400, a decrease of 10,500 from the previous period, representing a decline of 7.96% [2] - The closing price of Yuheng Pharmaceutical on the reporting date was 3.73 yuan, down 0.80%, with a cumulative increase of 0.54% since the concentration of shares began [2] - The stock experienced 4 days of price increases and 7 days of declines during the reporting period [2] Group 3 - The latest margin trading data as of August 15 shows a total margin balance of 563 million yuan, with a financing balance of 563 million yuan, indicating an increase of 131 million yuan, or 30.31%, since the concentration of shares began [2] Group 4 - In the first quarter, Yuheng Pharmaceutical reported total revenue of 551 million yuan, a year-on-year decrease of 7.06%, while net profit was 60.25 million yuan, a year-on-year increase of 15.24% [2] - The basic earnings per share were 0.0274 yuan, and the weighted average return on net assets was 3.08% [2]

Group 1 - The stock price of Yuheng Pharmaceutical is reported at 3.75 yuan as of August 5, 2025, reflecting a decrease of 0.06 yuan or 1.57% from the previous trading day [1] - The company operates in the chemical pharmaceutical sector, focusing on drug research, production, and sales [1] - Yuheng Pharmaceutical has not met the conditions for dividend distribution due to accumulated unremedied losses being negative [1] Group 2 - The company completed a share repurchase plan in March 2025, buying back a total of 32.3072 million shares at a cost of approximately 80 million yuan [1] - On August 5, the stock experienced a rapid rebound with an increase of over 2% within five minutes, but subsequently fell back [1] - The net outflow of main funds on that day was 7.9332 million yuan, while there was a net inflow of 100 million yuan over the past five days [1]

证券日报网讯 誉衡药业8月5日在互动平台回答投资者提问时表示，公司目前累计未弥补亏损为负，暂 不满足分红条件。但公司推出的股份回购方案已于2025年3月实施完毕，累计使用资金约8，000万元， 回购股份数量3，230.72万股。根据相关法律、法规的规定，公司以集中竞价方式回购公司股份视同现 金分红，公司通过本次回购计划，积极回馈长期以来支持与信任公司的广大投资者。 （编辑 王雪儿） ...

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Core Insights - Harbin Yuheng Pharmaceutical Co., Ltd. (誉衡药业) reported a stock price of 4.04 yuan as of August 1, 2025, reflecting an increase of 8.89% with a turnover rate of 22.96% and a trading volume of 4.8238 million hands, amounting to 1.913 billion yuan in transaction value [1] Financial Performance - For Q1 2025, the company recorded total revenue of 551 million yuan, a year-on-year decrease of 7.06%, while net profit attributable to shareholders was 60.2523 million yuan, showing a year-on-year increase of 15.24%. The non-recurring net profit was 49.733 million yuan, up 54.74% year-on-year [1] - The company's liquidity ratios include a current ratio of 1.061, a quick ratio of 0.853, and a debt-to-asset ratio of 31.97% [1] Investment and Intellectual Property - Harbin Yuheng Pharmaceutical has made investments in 19 companies and participated in 423 bidding projects. The company holds 701 trademark registrations and 28 patents, along with 9 administrative licenses [2]

Group 1 - The core viewpoint of the news highlights the recent stock performance of Yuheng Pharmaceutical, which saw an increase of 8.01% on July 31, reaching a price of 3.91 yuan per share with a trading volume of 8.85 billion yuan and a turnover rate of 11.38%, resulting in a total market capitalization of 87.81 billion yuan [1] - Yuheng Pharmaceutical, based in Harbin, Heilongjiang Province, is a modern pharmaceutical company that integrates research, production, and sales, initially focusing on orthopedic treatments and expanding into cardiovascular and other therapeutic areas, establishing a product cluster that includes cardiovascular, musculoskeletal, and nutritional medications [1] - The company emphasizes strict quality management and international innovation, having established production bases and marketing systems that comply with GMP and GSP standards, while actively developing CMO platforms and chronic disease services, aiming to become a leading pharmaceutical enterprise in China with an international perspective [1] Group 2 - As of May 30, Yuheng Pharmaceutical had 107,100 shareholders, with an average of 19,600 circulating shares per shareholder [2] - For the first quarter of 2025, Yuheng Pharmaceutical reported a revenue of 551 million yuan, a year-on-year decrease of 7.06%, while the net profit attributable to shareholders was 60.25 million yuan, reflecting a year-on-year increase of 15.24% [2]

Core Points - The stock price of Yuheng Pharmaceutical (002437) closed at 3.62 yuan on July 30, 2025, with an increase of 2.55% and a turnover rate of 12.89% [1] - The company reported a total revenue of 551 million yuan for Q1 2025, a year-on-year decrease of 7.06%, while net profit attributable to shareholders was 60.25 million yuan, an increase of 15.24% [1] - The company has a registered capital of 2.27 billion yuan and a paid-in capital of 105 million yuan [1] Financial Performance - Total revenue for Q1 2025: 5.51 billion yuan, down 7.06% year-on-year [1] - Net profit attributable to shareholders: 6025.23 million yuan, up 15.24% year-on-year [1] - Non-recurring net profit: 4973.30 million yuan, up 54.74% year-on-year [1] - Current ratio: 1.061, quick ratio: 0.853, debt-to-asset ratio: 31.97% [1] Investment and Intellectual Property - Yuheng Pharmaceutical has invested in 19 companies and participated in 423 bidding projects [2] - The company holds 701 trademark registrations and 28 patents [2] - Additionally, it possesses 9 administrative licenses [2]

Group 1: Stock Performance - Yiming Pharmaceutical achieved a 10.00% increase over two consecutive days, driven by developments in Tibet and medical technology [3] - Kantai Medical saw a first board listing with a 20.03% rise, attributed to medical device advancements [4] - Zhengchuan Co. also debuted on the first board with a 9.99% increase, linked to medicinal glass [3] - Yuheng Pharmaceutical and Tianmu Pharmaceutical both recorded first board listings with increases of 10.09% and 10.00% respectively, related to the pharmaceutical sector [3] Group 2: AI and Robotics - Zhi Zhen Technology and Zhongdian Xinlong both debuted on the first board with a 10.01% increase, associated with computing power and machine learning [6] - Hubei Broadcasting and Duolun Technology also saw first board listings with increases of 10.04% and 9.95%, driven by computing power and AI applications [7] - The M-Robots open-source project was announced, aiming to create a unified robot operating system [11] Group 3: Infrastructure and Energy - The announcement of a 1.2 trillion yuan investment in a super hydropower project has led to significant interest in related stocks [13][16] - Nanfang Road Machinery and Tuoshan Heavy Industry both achieved consecutive board listings with increases of 9.99% and 10.01%, linked to engineering machinery [15] Group 4: Tourism and Hospitality - The demand for various types of tourism, including educational and family trips, has surged, with national railways reporting 341 million passenger trips [18][19] - Sizhizang Tourism and Tianfu Cultural Tourism both recorded first board listings with increases of 9.99% and 10.04%, reflecting the growing tourism sector [20] Group 5: Market Trends - The stock market has shown a strong focus on sectors such as robotics, AI, and infrastructure, with multiple companies achieving significant stock price increases [22][23]